CA2678007A1 - Composes pyrrolo[2,3-b]pyridine, composes azaindoles utiles dans la synthese de ces composes pyrrolo[2,3-b]pyridine, leurs procedes de fabrication et leurs utilisations - Google Patents
Composes pyrrolo[2,3-b]pyridine, composes azaindoles utiles dans la synthese de ces composes pyrrolo[2,3-b]pyridine, leurs procedes de fabrication et leurs utilisations Download PDFInfo
- Publication number
- CA2678007A1 CA2678007A1 CA002678007A CA2678007A CA2678007A1 CA 2678007 A1 CA2678007 A1 CA 2678007A1 CA 002678007 A CA002678007 A CA 002678007A CA 2678007 A CA2678007 A CA 2678007A CA 2678007 A1 CA2678007 A1 CA 2678007A1
- Authority
- CA
- Canada
- Prior art keywords
- pyrrolo
- pyridine
- group
- pyrimidin
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0701138A FR2912744B1 (fr) | 2007-02-16 | 2007-02-16 | Composes pyrrolo°2,3-b!pyridine,composes azaindoles utiles dans la synthese de ces composes pyrrolo°2,3-b!pyridine, leurs procedes de fabrication et leurs utilisations. |
| FR0701138 | 2007-02-16 | ||
| PCT/FR2008/000197 WO2008129152A1 (fr) | 2007-02-16 | 2008-02-14 | Composes pyrrolo[2,3-b]pyridine, composes azaindoles utiles dans la synthese de ces composes pyrrolo[2,3-b]pyridine, leurs procedes de fabrication et leurs utilisations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2678007A1 true CA2678007A1 (fr) | 2008-10-30 |
Family
ID=38515529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002678007A Abandoned CA2678007A1 (fr) | 2007-02-16 | 2008-02-14 | Composes pyrrolo[2,3-b]pyridine, composes azaindoles utiles dans la synthese de ces composes pyrrolo[2,3-b]pyridine, leurs procedes de fabrication et leurs utilisations |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20100184790A1 (enExample) |
| EP (1) | EP2125803B1 (enExample) |
| JP (1) | JP2010518153A (enExample) |
| CA (1) | CA2678007A1 (enExample) |
| FR (1) | FR2912744B1 (enExample) |
| WO (1) | WO2008129152A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009266806A1 (en) * | 2008-07-03 | 2010-01-07 | Exelixis Inc. | CDK modulators |
| CA2767089A1 (en) * | 2009-07-15 | 2011-01-20 | Abbott Laboratories | Pyrrolopyridine inhibitors of kinases |
| CN105732639A (zh) | 2012-06-29 | 2016-07-06 | 辉瑞大药厂 | 作为LRRK2抑制剂的4-(取代的氨基)-7H-吡咯并〔2,3-d〕嘧啶类 |
| FR2999575A1 (fr) | 2012-12-18 | 2014-06-20 | Centre Nat Rech Scient | 3,5-diaryl-azaindoles comme inhibiteurs de la proteine dyrk1a pour le traitement des deficiences cognitives liees au syndrome de down et a la maladie d'alzheimer |
| EP3083618B1 (en) * | 2013-12-17 | 2018-02-21 | Pfizer Inc | Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors |
| WO2016004272A1 (en) | 2014-07-02 | 2016-01-07 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| CN108137586B (zh) | 2015-09-14 | 2021-04-13 | 辉瑞大药厂 | 作为LRRK2抑制剂的新颖咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啶衍生物 |
| FR3041640B1 (fr) * | 2015-09-30 | 2019-05-17 | Les Laboratoires Servier | NOUVEAUX DERIVES DE PYRROLO[2,3-d]PYRIMIDINE, LEUR PROCEDE DE PREPRATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT |
| EP3383875B1 (en) | 2015-11-30 | 2022-02-09 | Council Of Scientific & Industrial Research | 3-pyrimidinyl pyrrolo [2,3-b] pyridine as anticancer agents and the process for the preparation thereof |
| WO2018136202A2 (en) * | 2016-12-23 | 2018-07-26 | Plexxikon Inc. | Compounds and methods for cdk8 modulation and indications therefor |
| DK3604304T3 (da) * | 2017-03-23 | 2022-10-31 | Daegu Gyeongbuk Medical Innovation Found | Pyrrolo-pyridinderivatforbindelse, fremgangsmåde til fremstilling deraf og farmaceutisk sammensætning indeholdende denne som aktiv ingrediens til forebyggelse eller behandling af proteinkinase-relaterede sygdomme |
| EP3668882A1 (en) | 2017-08-18 | 2020-06-24 | Cancer Research Technology Limited | Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer |
| CN110759892B (zh) * | 2018-07-26 | 2022-09-13 | 南开大学 | Meridianin类衍生物及其制备和在防治植物病毒病菌病中的应用 |
| CN109096257B (zh) * | 2018-08-09 | 2020-02-21 | 山东博苑医药化学有限公司 | Meridianin类生物碱及其衍生物在防治植物病毒病菌病中的应用 |
| EP3915985A4 (en) | 2019-01-18 | 2022-09-28 | Voronoi Co., Ltd. | PYRROLOPYRIDE DERIVATIVE AND USE THEREOF FOR THE PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED DISEASES |
| CN109879874A (zh) * | 2019-03-05 | 2019-06-14 | 常州大学 | 一种Meriolin的合成方法 |
| KR20220081631A (ko) | 2020-12-09 | 2022-06-16 | 보로노이 주식회사 | 염증성 질환의 예방 및/또는 치료를 위한 피롤로-피리딘 유도체 화합물의 신규 용도 |
| WO2022245776A1 (en) * | 2021-05-20 | 2022-11-24 | Saint John's Cancer Institute | Anti-cdk inhibitors for cancer treatment |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006050076A1 (en) * | 2004-10-29 | 2006-05-11 | Janssen Pharmaceutica, N.V. | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
| AU2006247322A1 (en) * | 2005-05-16 | 2006-11-23 | Irm Llc | Pyrrolopyridine derivatives as protein kinase inhibitors |
| CA2632284A1 (en) * | 2005-11-30 | 2007-06-07 | F. Hoffmann-La Roche Ag | 3-amino-2-arylpropyl azaindoles and uses thereof |
-
2007
- 2007-02-16 FR FR0701138A patent/FR2912744B1/fr not_active Expired - Fee Related
-
2008
- 2008-02-14 CA CA002678007A patent/CA2678007A1/fr not_active Abandoned
- 2008-02-14 US US12/526,446 patent/US20100184790A1/en not_active Abandoned
- 2008-02-14 JP JP2009549445A patent/JP2010518153A/ja active Pending
- 2008-02-14 EP EP08775557.5A patent/EP2125803B1/fr not_active Not-in-force
- 2008-02-14 WO PCT/FR2008/000197 patent/WO2008129152A1/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| FR2912744B1 (fr) | 2012-09-07 |
| EP2125803A1 (fr) | 2009-12-02 |
| JP2010518153A (ja) | 2010-05-27 |
| WO2008129152A1 (fr) | 2008-10-30 |
| US20100184790A1 (en) | 2010-07-22 |
| EP2125803B1 (fr) | 2013-04-10 |
| FR2912744A1 (fr) | 2008-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2678007A1 (fr) | Composes pyrrolo[2,3-b]pyridine, composes azaindoles utiles dans la synthese de ces composes pyrrolo[2,3-b]pyridine, leurs procedes de fabrication et leurs utilisations | |
| DE69815317T2 (de) | Pyrrolo[2,3-d]pyrimidine und ihre verwendung als tyrosinkinase-inhibitoren | |
| JP5943053B2 (ja) | フェノキシメチル複素環化合物 | |
| EP3697786B1 (en) | Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase | |
| EP4285996A2 (en) | Inhibitors of activin receptor-like kinase | |
| JP2021105002A (ja) | イミダゾピリダジン化合物 | |
| TW200520758A (en) | Novel pharmaceuticals | |
| JP2011526295A (ja) | 5員および6員複素環化合物 | |
| WO2004043936A1 (ja) | Plk阻害剤 | |
| TW201213324A (en) | Fused heterocyclic compounds | |
| FR2906250A1 (fr) | Derives de 2-aryl-6phenyl-imidazo(1,2-a) pyridines, leur preparation et leur application en therapeutique | |
| CA2766909C (fr) | Nouveaux derives de 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one,leur preparation et leur utilisation pharmaceutique | |
| CN103619841A (zh) | 杂芳基化合物及其使用方法 | |
| JP2020524148A (ja) | 置換5−シアノインドール化合物及びその使用 | |
| TW202019913A (zh) | 細胞壞死抑制劑及其製備方法和用途 | |
| JP2008533172A (ja) | チロシン/スレオニンキナーゼ阻害剤、特にB−RAFキナーゼ阻害剤としての、N−[3−(1−アミノ−5,6,7,8−テトラヒドロ−2,4,4b−トリアザフルオレン−9−イル)−フェニル]ベンズアミド | |
| JP2021535154A (ja) | バニン阻害剤としてのヘテロ芳香族化合物 | |
| US9994590B2 (en) | Substituted [1,2,4]triazolo[1,5-a]pyrazines as phosphodiesterase inhibitors | |
| TW201643143A (zh) | 抑制氧化壓迫引發的神經細胞死亡之化合物 | |
| KR20150036126A (ko) | 포스포디에스테라아제 10 효소의 억제제 | |
| HK1200815A1 (en) | [1,2,4]triazolopyridines and their use as phospodiesterase inhibitors | |
| RU2833338C1 (ru) | Конденсированное трициклическое соединение и его применение в медицине | |
| CN110627795A (zh) | 磷酸二酯酶抑制剂及其用途 | |
| TW202227447A (zh) | 嘧啶酮類化合物及其用途 | |
| TW201211043A (en) | Tetrahydro-imidazo[1,5-a]pyrazine derivatives salts, preparation process and pharmaceutical use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| EEER | Examination request |
Effective date: 20121220 |
|
| FZDE | Discontinued |
Effective date: 20150216 |